Core Insights - Lantheus Holdings, Inc. (NASDAQ:LNTH) is recognized as one of the seven cheap pharmaceutical stocks to buy according to hedge funds, ranking fourth on the list [2] - TD Cowen has lowered its price target for LNTH from $80 to $75 while maintaining a Buy rating, reflecting adjustments in their financial model ahead of the company's fourth-quarter results [2][8] - The company has completed the divestiture of its Single Photon Emission Computed Tomography (SPECT) business to SHINE Technologies, which may allow it to focus on more profitable growth areas [3] Company Strategy - Lantheus is prioritizing the growth of its commercial portfolio in PET radiodiagnostics and microbubble products for contrast-enhanced ultrasound procedures [4] - The company plans to invest in and develop its pipeline of radiopharmaceuticals to support long-term growth in precision imaging and targeted treatments [4] - Lantheus aims to leverage its expertise in nuclear medicine to create innovative diagnostic and therapeutic solutions for patients [4][5]